Top News

Sun Pharmaceutical Industries Limited announced an interim dividend of ₹11.00 per equity share for the financial year FY26 following the approval of its third-quarter results for the period ended December 31, 2025.

The dividend was declared by the company’s Board of Directors at its meeting held today. This compares with an interim dividend of ₹10.50 per share declared for the previous financial year, indicating an increase of ₹0.50 per share on a year-on-year basis.

The interim dividend declaration comes alongside the company’s Q3FY26 consolidated results. For Q3FY26, Sun Pharma recorded revenue from operations of ₹15,520.5 crore, compared with ₹13,675.4 crore in the corresponding quarter of the previous financial year. This represents a year-on-year increase of 13.5%, driven by performance across India, Emerging Markets, and Global Innovative Medicines.

Total income for the quarter stood at ₹16,099.4 crore, up from ₹14,141.1 crore in Q3FY25. Operating expenses during the quarter amounted to ₹11,382.7 crore, compared with ₹10,348.5 crore in the same period last year.

Earnings before interest, tax, depreciation, and amortisation for the quarter came in at ₹4,948.5 crore, marking a 23.4% year-on-year increase. The EBITDA margin improved to 31.9% in Q3FY26, compared with approximately 29.9% in Q3FY25, reflecting higher operating leverage during the quarter.

Profit before exceptional items and tax rose to ₹4,716.6 crore, compared with ₹3,792.6 crore in the year-ago quarter, registering a YoY growth of 24.4%. After accounting for taxes, exceptional items, and minority interests, net profit for the quarter stood at ₹3,368.8 crore, up 16.0% year-on-year from ₹2,903.4 crore.